First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004,St Thomas’ Hospital,London,UK

Contreras G , Roth D , Pardo V , Striker LG , Schultz DR. Lupus nephritis: a clinical review for practicing nephrologists . Clin Nephrol 2002; 57: 95-107 .

Karim Y , D’Cruz DP . The NIH pulse cyclophosphamide regime: the end of an era? Lupus 2004; 13: 1-3 .

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . N Engl J Med 2000; 343: 1156-1162 .

Austin HA 3rd , Klippel JH , Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . N Engl J Med 1986; 314: 614-619 .

Boumpas DT , Austin HA 3rd , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340: 741-745 .

Gourley MF , Austin HA 3rd , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med 1996; 125: 549-575 .

Illei GG , Austin HA , Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis . Ann Intern Med 2001; 135: 248-257 .

Flanc RS , Roberts MA , Strippoli GF , Chadban SJ , Kerr PG , Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials . Am J Kidney Dis 2004; 43: 197-208 .

El Hachmi M , Jadoul M , Lefebvre C , Depresseux G , Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome . Lupus 2003; 12: 692-696 .

Houssiau FA , Vasconcelos C , D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum 2002; 46: 2121-2131 .

Fraenkel L , Bogardus S , Concato J. Patient preferences for treatment of lupus nephritis . Arthritis Rheum 2002; 47: 421-428 .

Houssiau FA , D’Cruz DP , Haga HJ , Hughes GR. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study . Lupus 1991; 1: 31-35 .

Martin-Suarez I , D’Cruz D , Mansoor M , Fernandes AP , Khamashta MA , Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide . Ann Rheum Dis 1997; 56: 481-487 .

Haga HJ , D’Cruz D , Asherson R , Hughes GR. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis . Ann Rheum Dis 1992; 51: 885-888 .

Ioannidis JP , Boki KA , Katsorida ME. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide . Kidney Int 2000; 57: 258-264 .

Ginzler EM , Aranow C , Buyon J. A multicenter study of mycophenolate mophetil (MMF) vs. intravenous cyclophosphamide (CYC) as induction therapy for severe lupus nephritis (LN): preliminary results . Arthritis Rheum 2003; 48: S1690-S1690 .

Ginzler EM , Aranow C , Merrill JT , Orloff K , Henry D. Toxicity and tolerability of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (CYC) in a multicenter trial as induction therapy for lupus nephritis (LN) . Arthritis Rheum 2003; 48: S1515-S1515 .

Contreras G , Pardo V , Leclercq B et al. Sequential therapies for proliferative lupus nephritis . N Engl J Med 2004; 350: 971-980 .

Ferro ML , Karim MY , Abbs IC , D’Cruz D , Khamashta MA , Hughes GRV. Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis . Arthritis Rheum 2003; 48: S1520-S1520 .

Karim MY , Alba P , Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents . Rheumatology (Oxford) 2002; 41: 876-882 .

Bijl M , Horst G , Bootsma H , Limburg PC , Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk . Ann Rheum Dis 2003; 62: 534-539 .